Scilex Holding (SCLXW) Preferred Stock Liabilities (2021 - 2022)
Scilex Holding (SCLXW) recorded quarterly Preferred Stock Liabilities of $101.3 million in Q3 2022, up 1.1% quarter-over-quarter from $100.2 million in Q2 2022, and down 27.33% on a YoY basis from $139.4 million in Q3 2021.
Scilex Holding (SCLXW) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
Scilex Holding's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $101.3 million for Q3 2022.
- In Q3 2022, Preferred Stock Liabilities fell 27.33% year-over-year to $101.3 million; the TTM figure through Sep 2022 stood at $101.3 million (down 27.33% YoY), while the FY2021 annual figure was $139.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $101.3 million for Q3 2022 at Scilex Holding, up from $100.2 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $140.4 million in Q1 2022 to a low of $13.4 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | - |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Scilex Holding | - | - | 4.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 100.19 Mn |
| Mar 31, 2022 | 140.42 Mn |
| Dec 31, 2021 | 139.38 Mn |
| Sep 30, 2021 | 139.38 Mn |
| Jun 30, 2021 | 13.39 Mn |
| Mar 31, 2021 | 139.38 Mn |